IOA-244 (PI3Kδ inhibitor)

Current understanding

To be populated as evidence accumulates.

2026-05-19 — TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea: cross-connection with tgr-1202-pi3k-delta-inhibitor-mpn: Both are selective PI3Kδ inhibitors being combined with ruxolitinib in MPN trials, forming a PI3Kδ + JAK class of combination strategies. (novelty: 3)
2026-03-30 — A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers: Phase I trial (trial-early): IOA-244, a selective PI3Kδ inhibitor, being evaluated as monotherapy and in combination with ruxolitinib in primary myelofibrosis (alongside other tumour-type arms), assessing safety and anti-tumour immune response — represents a first-in-class PI3K-AKT + JAK-STAT dual targeting strategy in MPN. (novelty: 4)